These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24486168)

  • 1. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Okada K; Kimura T; Mikamo H; Kasahara K; Seki M; Takakura S; Tokimatsu I; Ohmagari N; Takahashi Y; Matsumoto K; Igarashi M; Kobayashi M; Hamada Y; Mochizuki T; Kimura M; Nishi Y; Tanigawara Y; Takesue Y; ;
    J Infect Chemother; 2014 Jan; 20(1):1-5. PubMed ID: 24486168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study.
    Matsumoto T; Hanaki H; Kimura T; Nemoto M; Higashihara M; Yokota H; Oda S; Akiyama N; Miyao N; Yoshida M; Yukioka T; Soma K; Ohyashiki K; Suzuki Y; Arai T; Ikegami K; Ichiwata T; Otsuka Y; Kobayashi M; Totsuka K; Sunakawa K;
    J Infect Chemother; 2013 Feb; 19(1):128-37. PubMed ID: 23263188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage regimen of arbekacin for methicillin-resistant Staphylococcus aureus infection in newborns and infants.
    Yoshida K; Minowa H; Ebisu R; Uchida Y; Takahashi Y; Yoshioka A
    Pediatr Int; 2004 Dec; 46(6):645-9. PubMed ID: 15660861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.
    Miura K; Nakagawa M; Takahashi H; Uchino Y; Kodaira H; Iriyama N; Sakagami M; Ohtake S; Kobayashi S; Hojo A; Kurita D; Kobayashi Y; Kusuda M; Hirabayashi Y; Hatta Y; Takei M
    Int J Hematol; 2016 Mar; 103(3):334-40. PubMed ID: 26715149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of trends and factors associated with therapeutic drug monitoring (TDM) implementation for arbekacin treatment using a large Japanese medical claims database.
    Ito S; Goto R; Inose R; Kusama Y; Ono A; Koizumi R; Ishikane M; Ohmagari N; Muraki Y
    J Infect Chemother; 2022 Sep; 28(9):1266-1272. PubMed ID: 35606308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group].
    Morimoto K; Nakatani S; Kaji M; Kinoshita H; Fujimoto M; Hirata S; Ueda T; Tamate S; Yamazaki O
    Jpn J Antibiot; 1994 Jun; 47(6):826-36. PubMed ID: 8072193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide investigation in Japan on the efficacy of arbekacin in methicillin-resistant Staphylococcus aureus infections.
    Hayashi I; Inoue M; Hashimoto H
    Drugs Exp Clin Res; 1994; 20(6):225-32. PubMed ID: 7758394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kanamycin and its derivative, arbekacin: significance and impact.
    Hotta K; Kondo S
    J Antibiot (Tokyo); 2018 Mar; 71(4):417-424. PubMed ID: 29402999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of arbekacin in deep MRSA infection. Including follow-up study after the termination of chemotherapy].
    Kuwabara M; Konishi F; Yokoyama T; Kodama T; Santoh T; Nakai S; Miyoshi N; Kurimura T; Miyazawa T; Arita K
    Jpn J Antibiot; 1994 Jun; 47(6):771-80. PubMed ID: 8072186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical investigation of arbekacin sulfate based on Cmax/MIC].
    Kimura M; Yamagishi Y; Kawasumi N; Mikamo H
    Jpn J Antibiot; 2012 Aug; 65(4):263-9. PubMed ID: 23259256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical effect of arbekacin on MRSA infections after gastrointestinal surgery].
    Ochiai M; Tanimura H; Noguchi K; Takifuji K; Konishi R; Ohkouchi N; Kouno N; Ohnishi H; Shimada K; Kasitani M
    Jpn J Antibiot; 1994 Jun; 47(6):837-43. PubMed ID: 8072194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy of arbekacin in patients with methicillin-resistant Staphylococcus aureus infections. Research Group of MRSA Forum].
    Nasuhara K; Takatsuka K; Takatsuka N; Teraoka M; Tokita S; Shinohara M; Azuma E; Saijo N; Sone H; Saito I
    Jpn J Antibiot; 1994 Jun; 47(6):720-30. PubMed ID: 8072180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nationwide investigation in Japan of the status of MRSA infections and usefulness of arbekacin].
    Hayashi I; Inoue M; Hashimoto H
    Jpn J Antibiot; 1994 Jun; 47(6):595-605. PubMed ID: 8072167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of arbekacin, a new aminoglycoside antibiotic, in surgical patients with MRSA infections].
    Ishikawa S; Yura J; Shinagawa N; Mizuno A; Mashita K; Hori K
    Jpn J Antibiot; 1994 Jun; 47(6):820-5. PubMed ID: 8072192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical effect of the combined therapy of arbekacin and imipenem/cilastatin against methicillin-resistant Staphylococcus aureus].
    Hashimoto A; Ohtsubo T; Tomono K; Kaku M; Koga H; Kohno S; Hara K; Sugiyama H; Taira K; Inoue Y
    Jpn J Antibiot; 1994 Jun; 47(6):804-12. PubMed ID: 8072190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA].
    Ishii T; Takayama Y; Takase Y; Orikasa Y
    Jpn J Antibiot; 1994 Jun; 47(6):647-54. PubMed ID: 8072173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man].
    Totsuka K; Shimizu K; Mitomi N; Niizato T; Araake M
    Jpn J Antibiot; 1994 Jun; 47(6):676-92. PubMed ID: 8072176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection.
    Yamamoto Y; Izumikawa K; Hashiguchi K; Fukuda Y; Kobayashi T; Kondo A; Inoue Y; Morinaga Y; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yanagihara K; Kohno S
    J Infect Chemother; 2012 Apr; 18(2):241-6. PubMed ID: 22398881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of arbekacin for Gram-negative bacteria.
    Hamada Y; Tamura K; Koyama I; Kuroyama M; Yago K; Sunakawa K
    J Infect Chemother; 2011 Dec; 17(6):876-9. PubMed ID: 21667069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of arbekacin for staphylococcal infection in the NICU.
    Suzuki K
    Pediatr Int; 2003 Jun; 45(3):301-6. PubMed ID: 12828585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.